PPIDT00190
Drug Information
| Name | Dalbavancin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06219 |
| Type | small molecule |
| Indication | Dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. Dalbavancin is not active against gram-negative bacteria; therefore, combination therapy may be clinically indicated if the ABSSSI is polymicrobial and includes a suspected or documented gram-negative pathogen [F2356]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin and other antibacterial drugs, dalbavancin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria [FDA Label, F2356]. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy [FDA Label, F2356]. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy [FDA Label, F2356]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Parenteral |
500 mg
|
| Injection, powder, for solution | Intravenous |
500 mg/25mL
|
| Injection, powder, for solution | Intravenous |
500 mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
500 MG
|
| Powder, for solution | Intravenous |
500 mg / vial
|